Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.

Authors:
Anders E Junker
Anders E Junker
Center for Diabetes Research
Mette Christensen
Mette Christensen
University of Copenhagen
Denmark
Flemming Wibrand
Flemming Wibrand
Copenhagen University Hospital Rigshospitalet
Denmark
Allan M Lund
Allan M Lund
National Hospital
Katrine D Galsgaard
Katrine D Galsgaard
University of Copenhagen
København | Denmark
Jens J Holst
Jens J Holst
University of Copenhagen
Denmark

Am J Physiol Gastrointest Liver Physiol 2018 01 28;314(1):G91-G96. Epub 2017 Sep 28.

Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Patients with type 2 diabetes (T2D) and patients with nonalcoholic fatty liver disease (NAFLD) frequently exhibit elevated plasma concentrations of glucagon (hyperglucagonemia). Hyperglucagonemia and α-cell hyperplasia may result from elevated levels of plasma amino acids when glucagon's action on hepatic amino acid metabolism is disrupted. We therefore measured plasma levels of glucagon and individual amino acids in patients with and without biopsy-verified NAFLD and with and without type T2D. Fasting levels of amino acids and glucagon in plasma were measured, using validated ELISAs and high-performance liquid chromatography, in obese, middle-aged individuals with I) normal glucose tolerance (NGT) and NAFLD, II) T2D and NAFLD, III) T2D without liver disease, and IV) NGT and no liver disease. Elevated levels of total amino acids were observed in participants with NAFLD and NGT compared with NGT controls (1,310 ± 235 µM vs. 937 ± 281 µM, P = 0.03) and in T2D and NAFLD compared with T2D without liver disease (1,354 ± 329 µM vs. 511 ± 235 µM, P < 0.0001). Particularly amino acids with known glucagonotropic effects (e.g., glutamine) were increased. Plasma levels of total amino acids correlated to plasma levels of glucagon also when adjusting for body mass index (BMI), glycated hemoglobin (Hb), and cholesterol levels (β = 0.013 ± 0.007, P = 0.024). Elevated plasma levels of total amino acids associate with hyperglucagonemia in NAFLD patients independently of glycemic control, BMI or cholesterol - supporting the potential importance of a "liver-α-cell axis" in which glucagon regulates hepatic amino acid metabolism. Fasting hyperglucagonemia as seen in T2D may therefore represent impaired hepatic glucagon action with increasing amino acids levels. NEW & NOTEWORTHY Hypersecretion of glucagon (hyperglucagonemia) has been suggested to be linked to type 2 diabetes. Here, we show that levels of amino acids correlate with levels of glucagon. Hyperglucagonemia may depend on hepatic steatosis rather than type 2 diabetes.

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpgi.00216.2017DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
January 2018
28 Reads

Publication Analysis

Top Keywords

amino acids
40
plasma levels
20
liver disease
20
type diabetes
16
total amino
12
glucagon hyperglucagonemia
12
levels glucagon
12
amino
12
levels
12
levels total
12
acids
10
elevated levels
8
glucagon
8
elevated plasma
8
acid metabolism
8
t2d liver
8
t2d nafld
8
amino acid
8
hepatic amino
8
levels amino
8

Similar Publications